00000000nam 2200000zi 4500
0019.920443
003CaOODSP
00520230529150717
006m     o  d f      
007cr mn|||||||||
008230227t20232023onc     ob   f000 0 eng d
020 |a9780660478159|q(report)
020 |a9780660478166|q(summary)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP5-157/1-2023E-PDF
0861 |aHP5-157/2-2023E-PDF
24500|aGuidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19.
264 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2023.
264 4|c©2023
300 |a1 online resource (17 pages) + |e1 summary (5 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |a"Published: March 3, 2023."
500 |a"On cover: Protecting and empowering Canadians to improve their health."
500 |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
500 |a"Summary of National Advisory Committee on Immunization (NACI) statement of March 3, 2023."
500 |aIssued also in French under title: Directives sur une dose de rappel supplémentaire du vaccin contre la COVID-19 au printemps 2023 pour les personnes présentant un risque élevé de maladie sévère due à la COVID-19.
504 |aIncludes bibliographical references (pages 13-17).
520 |a"On January 20, 2023, NACI published Guidance on COVID-19 vaccine booster doses: initial considerations for 2023. This guidance consolidated and reinforced previously established booster dose recommendations and extended the fall booster program for those who had not yet received a 2022 recommended booster dose into 2023"--Background, page 4.
650 0|aCOVID-19 (Disease)|xVaccination|zCanada.
650 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
7101 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body.
77508|tDirectives sur une dose de rappel supplémentaire du vaccin contre la COVID-19 au printemps 2023 pour les personnes présentant un risque élevé de maladie sévère due à la COVID-19.|w(CaOODSP)9.920444
85640|qPDF|s624 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-157-1-2023-eng.pdf|zGuidance
85640|qPDF|s414 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-157-2-2023-eng.pdf|zSummary
986 |a220791
986 |a220793